ClinicalTrials.gg
CompletedNCT01640067hNSCALSUpdated Dec 30, 2015

Human Neural Stem Cell Transplantation in Amyotrophic Lateral Sclerosis (ALS)

A Phase 1 interventional study of Human Neural Stem Cells in Amyotrophic Lateral Sclerosis, sponsored by Azienda Ospedaliera Santa Maria, Terni, Italy. Completed at 1 site in Italy. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-12-30.

Sponsored by Azienda Ospedaliera Santa Maria, Terni, Italy · Phase 1 and Interventional

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 89 studies in Amyotrophic Lateral Sclerosis with a site in Italy — 27 open to participants now, 36 under way, 7 of them phase 3. Amyotrophic Lateral Sclerosis · Italy.

Enrollment
67th of 69
18 · median 87
Started
2011
the only one that year
Phase 1
2 of 89
none open now
Registered
13th of 89
by date

Among the 89 studies in Amyotrophic Lateral Sclerosis with a site in Italy, this one is the 67th largest by enrollment of the 69 interventional ones that give a count, is the only one that started in 2011, is one of 2 in phase 1, and was the 13th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

27 of the 89 studies in Amyotrophic Lateral Sclerosis with a site in Italy are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Amyotrophic Lateral Sclerosis with a site in Italy, or all of them as a file.
02

Study summary

Primary aim of the trial

  1. to verify safety and tolerability of expanded human fetal neural stem cells
  2. to verify safety and tolerability of a microsurgery human fetal neural stem cells transplantation model
  3. to recognize each change in patient's quality of life

Secondary aim of the trial

  1. assessment of the impact of human neural stem cells transplantation on the disability of ALS in a clinically significant and measurable way
  2. Assessment of the impact of human neural stem cells transplantation on mortality (all causes)
Read the detailed description

18 patients diagnosed as definite ALS according to the El Escorial criteria will be recruited during two years. The patients will be divided into 3 groups with different severity. Each group will be less compromised than the group that went before them. Their breathing measurements must be at least 60%. Subjects will receive injections of the human foetal neural stem cells into the spinal cord. A variety of tests and examinations will take place every month for the first year and every three months for the next two in order to monitor the course of the disease and the adverse events.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis

Keywords

  • amyotrophic lateral sclerosis
  • motor neuron disease
  • stem cells
  • safety
  • ALS-FRS-Functional scale R and FVC (%) variation
  • Survival analysis
  • Changes in quality of life scales
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of definite or possible ALS according to revised EL Escorial criteria
  • Age: 20-75 years
  • documented progression of disease during the last 6 months.
  • Absence of concomitant diseases
  • Adequate assurances of adherence to protocol
  • The patient must be able to communicate verbally or with the use of non-verbal communication system

Group 1

  • maximum score of 1 on walking item of ALS functional rating scale
  • forced vital capacity > or equal to 60

Group 2

  • forced vital capacity > or equal to 60
  • ambulation difficulties (maximum score of 2 on walking item of ALS functional rating scale)

Group 3

  • Independent ambulation (score 4 on a scale ALS-FRS)
  • forced vital capacity > or equal to 70

Exclusion criteria

Exclusion Criteria:

The presence of at least one of the following will lead to patient exclusion.

  1. psychiatric diseases or other neurological diseases different from ALS
  2. other systemic diseases
  3. Neoplasms or other diseases reducing
  4. Antecedent polio infection
  5. , immunoglobulin or treatment
  6. involvement in other clinical trials
  7. 2 or more critical items in MMPI
  8. neuropsychological evaluation suggestive of mental deterioration or cognitive sphere disturbance.
  9. Impediments to MRI
  10. patients unable to understand form and study aims.
  11. women who are pregnant or for the duration of the study. Non-pregnant status will be documented by beta-HCG negative test 7 days before treatment start
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Human Neural Stem Cells Suspension

    50,000 cells/µl. Patients received either unilateral or bilateral hNSCs microinjections (3 microinjections on each side) into the lumbar spinal cord. Each microinjection consisted of 15 µl of the above 50,000cells/µl suspension, yielding a total of 750,000 cells per injection site.

    Biological: Human Neural Stem Cells

Interventions

  • BiologicalHuman Neural Stem Cells

    Surgical microinjection of human neural stem cells on spinal cord of ALS patients

    Also known as: Human Neural Stem Cells Suspension

06

What researchers measure

Primary outcomes

  1. safety of a microsurgery human neural stem cells transplantation into spinal cord of ALS patients

    * Percentage of subjects (%) with treatment-related mortality defined as death due to procedure and not to the course of the disease * Number of adverse events related to the procedure * Changes in neuroradiological (MRI) and neurophysiological variables (SEP, MEP) * Changes in neuropsychological variables

    Time frame: Participants will be followed for at least 3 years. Monthly in the first year and every three months the following two years

07

Study locations

1 site
  • Azienda Ospedaliera Santa Maria
    Terni, 05100, Italy
08

References and documents

Publications

  • Gelati M, Profico D, Projetti-Pensi M, Muzi G, Sgaravizzi G, Vescovi AL. Culturing and expansion of "clinical grade" precursors cells from the fetal human central nervous system. Methods Mol Biol. 2013;1059:65-77. doi: 10.1007/978-1-62703-574-3_6. PubMed 23934834 ↗
  • Mazzini L, Gelati M, Profico DC, Sgaravizzi G, Projetti Pensi M, Muzi G, Ricciolini C, Rota Nodari L, Carletti S, Giorgi C, Spera C, Domenico F, Bersano E, Petruzzelli F, Cisari C, Maglione A, Sarnelli MF, Stecco A, Querin G, Masiero S, Cantello R, Ferrari D, Zalfa C, Binda E, Visioli A, Trombetta D, Novelli A, Torres B, Bernardini L, Carriero A, Prandi P, Servo S, Cerino A, Cima V, Gaiani A, Nasuelli N, Massara M, Glass J, Soraru G, Boulis NM, Vescovi AL. Human neural stem cell transplantation in ALS: initial results from a phase I trial. J Transl Med. 2015 Jan 27;13:17. doi: 10.1186/s12967-014-0371-2. PubMed 25889343 ↗
  • Gelati M, Profico DC, Ferrari D, Vescovi AL. Culturing and Expansion of "Clinical Grade" Neural Stem Cells from the Fetal Human Central Nervous System. Methods Mol Biol. 2022;2389:57-66. doi: 10.1007/978-1-0716-1783-0_5. PubMed 34558001 ↗
  • Robberecht W, Philips T. The changing scene of amyotrophic lateral sclerosis. Nat Rev Neurosci. 2013 Apr;14(4):248-64. doi: 10.1038/nrn3430. Epub 2013 Mar 6. PubMed 23463272 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2012
First posted
Jul 13, 2012
Start
Dec 2011
Primary completionActual
Dec 2015
CompletionActual
Dec 2015
Last update
Dec 30, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01640067
Lead sponsor
Azienda Ospedaliera Santa Maria, Terni, Italy
Collaborators
Azienda Ospedaliero Universitaria Maggiore della Carita, Università di Padova Italy
Responsible party
Angelo Luigi Vescovi (Scientific Director of Laboratorio Cellule Staminali, Cell Factory e Biobanca AOSP di Terni, Scientific Director IRCCS Casa Sollievo della Sofferenza S.Giovanni Rotondo Italy, Azienda Ospedaliera Santa Maria, Terni, Italy) — Principal investigator
First posted
Jul 13, 2012
Start date
Dec 2011
Primary completion
Dec 2015
Completion
Dec 2015
Last update
Dec 30, 2015

Study contacts

Angelo L Vescovi, Professor
principal investigator · IRCCS Casa Sollievo della Soffernza and AOSP Terni, Italy

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion